Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408453 | 0.77 | SLC6A3 (0.34) | MEN1POLBGAAKMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL6401099 | 0.76 | MEN1 (0.33) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL6403882 | 0.75 | MEN1 (0.32) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL6401595 | 0.74 | MEN1 (0.31) | MEN1POLBGAAKMT2A | |
| SCHEMBL6406550 | 0.74 | PTPN1 (0.33) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6408039 | 0.73 | SLC6A3 (0.34) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL9467530 | 0.73 | MEN1 (0.47) | MEN1POLBGAAKMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL6408025 | 0.72 | MEN1 (0.30) | MEN1POLBGAAKMT2A | |
| Hydrochloric Acid SCHEMBL6400795 | 0.71 | — | — | |
| SCHEMBL6406800 | 0.71 | PTPN1 (0.41) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844288-B2 | Process for the preparation of ligands for metallogene catalysts | BASELL POLYOLEFINE GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | EQUISTAR CHEMICALS, LP | 2003-08-21 | — | — | US | disclosed |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | RESCONI LUIGI (IT) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | MACF1, SDC1, SDC2 | MEN1 3563/4885POLB 614/4885GAA 4214/4885 |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | SDC1, SDC2, SDC4 | MEN1 2357/4885POLB 346/4885GAA 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.